Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03606642 · ClinicalTrials.gov registry record · Phase 2

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

A Phase 2 study, sponsored by HonorHealth Research Institute.

Terminated
Registry status
Phase 2
Development phase
50
Enrollment target

NCT03606642: Clinical Trial Phase 2 study, sponsored by HonorHealth Research Institute.

NCT03606642 is a Phase 2 study that was terminated before completion, run by HonorHealth Research Institute. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03606642, a Phase 2 study, was terminated before completion, sponsored by HonorHealth Research Institute.

TERMINATED
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).

Primary Outcome

Rate of cardiac death from 1 to 13 months post-index procedure in the "as treated" (eligible for 30 day DAPT cessation) population.

Interventions

  • DRUG Dual Antiplatelet (DAPT) Therapy
  • DEVICE The Synergy® stent

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-11-19
Est. Completion 2022-08-08
Phase Phase 2
HonorHealth Research Institute

20 total trials

Why NCT03606642 stopped before completion

NCT03606642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 2 interventions - of which Dual Antiplatelet (DAPT) Therapy is the first listed.

NCT03606642 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03606642 about?

NCT03606642 is a clinical study titled "SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy". The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).

What is the current status of trial NCT03606642?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-11-19. Estimated completion is 2022-08-08.

What interventions are being tested in trial NCT03606642?

The interventions under investigation include: Dual Antiplatelet (DAPT) Therapy (DRUG), The Synergy® stent (DEVICE).

Who is sponsoring clinical trial NCT03606642?

This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03606642's enrollment target sits among peer trials

50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03606642, the US trial registry maintained by the National Library of Medicine. NCT03606642 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.